Biopartner.co.uk, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK.
BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.
Biopartner.co.uk has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.
Mr Darius Bateson
Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.
- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.
- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.
The identified protein domains are used to quickly develop binding/activity assays for use in small molecule hit screening and/or to provide protein for structural studies. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging drug discovery programs. Domainex's approach enhances drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.
Doaminex also has an internal pipeline of novel cancer therapeutics. The lead program is available for licensing and is a kinase inhibitor against the targets TBK1/IKKe. Earlier programs in Domainex's pipeline include a number of epigenetic targets, such as the lysine methyltransferase, G9a.
Dr George BuckleySenior Business Development Manager
Dr Joanne McCuddenHead of Business Development
|Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses. The Contract Research Division delivers innovative preclinical research services in the areas of oncology, mucositis, inflammation.|
Dr Julie FosterBusiness Development Manager, Contract Research Services, Europe
|Fusion Antibodies is a CRO that offers a range of royalty free, fee-for-services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates.|
Dr Paul KerrManaging Director
Innova Biosciences Ltds core business is bioconjugation (antibody labeling) the joining of two molecules to form a hybrid conjugate™. Conjugates are used in hospital and research labs around the world; they also feature in consumer items such as pregnancy test kits (the conjugate is responsible for the blue line). Innova™s one-step conjugation method (Lightning-Link) massively simplifies the production of conjugates that are needed for research and immunodiagnostic applications. Innova also offers exclusive services for optimizing the performance of conjugates and developing more sensitive immunodiagnostic tests. Innova also sells several niche products to pharmaceutical research and development labs.
Mr Tom SpeedyCorporate Business Manager, BioPartner Advisory Board
Novozymes Biopharma develops and manufactures sustainable, safe, biological based ingredients and technologies to provide pharmaceutical and medical device manufacturers the knowledge-based solutions needed to address the challenges in developing innovative, safer, and more consistent final products. The company's large-scale manufacturing facilities worldwide are run to cGMP Q7 quality standards to ensure that customers receive the highest level of product quality and consistency, as well as the security of long-term supply. Novozymes’ customer-integrated approach combines the company’s scientific know-how and the specific needs of customers to deliver improved products and performance. By combining Novozymes’ unique knowledge around our biological solutions such as recombinant albumin, half-life extension and hyaluronic acid with the specific application knowledge of our customers, we work with companies to deliver improved performance and safety for next generation of medical device and pharmaceutical products.
Dr Dave MeadBusiness Development Director
|Ockham provides high-quality, global clinical research and strategic development services to pharmaceutical and biotechnology companies, assisting them in the achievement of their strategic planning, technology transfer, licensing, and regulatory planning.|
Ms Juliette Almond
Ms Andrea Cotton-Berry
Oxford BioMedica plc
|Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.|
Mr Peter NolanSVP -Commercial Development
Patheon (UK) Ltd
|Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides services to approximately 300 customers throughout the world.|